Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy Neoadjuvante Chemotherapie mit Cabazitaxel vor der radikalen Prostatektomie

Trial Profile

Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy Neoadjuvante Chemotherapie mit Cabazitaxel vor der radikalen Prostatektomie

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CLUBNET-CABAZ
  • Sponsors Sanofi
  • Most Recent Events

    • 12 Sep 2016 Status changed from suspended to discontinued as the investigator left the site
    • 15 Sep 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 12 Sep 2013 Planned end date changed from 12 Jun 2015 to 1 Aug 2018, as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top